In:
Cancer, Wiley, Vol. 121, No. 3 ( 2015-02), p. 403-412
Abstract:
Solitomab, a novel, bispecific, single‐chain antibody, is highly active against chemotherapy‐resistant epithelial ovarian carcinoma cell lines as well as unmanipulated malignant tumor cells in ascitic fluid. Solitomab may represent a novel, potentially highly effective, targeted agent for the treatment of chemotherapy‐resistant ovarian disease that overexpresses epithelial cell adhesion molecule.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1